14.02.2022 • News

Röhm Breaks Ground on Innovation Center in Worms

German methaycrylates specialist Röhm recently broke ground on a new state-of-the-art innovation center at Worms, Germany. The new facility, which will employ around 100 scientists, is designed to further expand its technology leadership, the company said.

The new center, set to be completed in early 2023, will house modern laboratories and pilot plants under one roof, thereby facilitating the development of new processes, products and applications with a view to breaking into new markets, Röhm said.

“By pooling our research activity at the biggest production site we have anywhere in the world, Röhm is set to expand on its leading market position,” said CEO Michael Pack. COO Hans-Peter Hauck added that the company’s global research activity underlines the Plexiglas-brand PMMA manufacturer’s aspiration to be a leading supplier in the field of methaycrylate chemicals.

As a globally-focused company with 15 production sites on four continents, Röhm is also strengthening its research activities in the US and China. The Darmstadt-based player commissioned a technological center in Shanghai last year and is currently building a new technology center in Wallingford, Connecticut, where research activity will kick off before the end of 2022.

Author: Dede Williams, Freelance Journalist

 

Start of construction: Groundbreaking ceremony in Worms. (c) Röhm
Start of construction: Groundbreaking ceremony in Worms. (c) Röhm

Company

Logo:

Röhm GmbH

Deutsche-Telekom-Allee 9
64295 Darmstadt
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.